The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Trial in progress: anti-SLAMF7 elotuzumab in JAK2-mutated myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer, Houston, TX, introduces the newly established pilot study (NCT04517851) of elotuzumab monotherapy in patients with JAK2 V617F-positive primary myelofibrosis or post-polycythemia vera/essential thrombocythemia myelofibrosis who are ineligible for JAK inhibitor therapy. Elotuzumab is an anti-SLAMF7 monoclonal antibody shown to inhibit the differentiation of myelofibrosis-patient derived fibrocytes in vitro. Additionally, patients with JAK2 V617F mutations have been shown to have high levels of elevated SLAMF7 expressing monocytes, thought to be possible fibrocyte precursors. Patients will receive elotuzumab until disease progression or unacceptable toxicity, up to 36 cycles. Overall response rate will be assessed as the primary study endpoint. Recruitment has begun, with 15 patients planned to be enrolled in total. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
